Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCSXI4)

Drug Name
Elezanumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Phase 2 [1]
Spinal cord injury ND51.2 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMCSXI4

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Repulsive guidance molecule A (RGMA) TTURJV4 RGMA_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT03737812) A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04295538) Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (ELASCI). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)